Two abstracts accepted for the American Association of Cancer Research 2020 (AACR 2020) has now been published online. The first study entitled “Evaluation of TK1 protein changes using the AroCell TK 210 ELISA in an acute myeloid leukemia (AML) xenograft model during...
Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers,...
The registration of TUBEX TF has been approved in Indonesia. Read the press release here
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with PHM Diagnostic Lab Ltd in Zimbabwe. Read the press release here
Redeye adds a new note to the previous analysis of Arocell on their website. See full here: Redeye.se
Inhibitors of Cyclin Dependent Kinases type 4 and 6 (CDK 4/6Is) have revolutionised the therapy of breast cancer. Combined with anti-oestrogen therapy they have significantly extended the mean and median life expectancies of women with breast cancer. This combination...
Or read it at DI.se
Kina har i många år varit ledande i användningen av tumörmarkörer. IDL Biotech har nu tecknat avtal med det kinesiska företaget ZECEN Biotech som avser en automatisering av analysprocessen för tumörmarkören TPS® på ZECEN Biotechs instrument. TPS® är en tumörmarkör som...
IDL has signed a new distribution agreement in Uganda Read the press release here
Achieving accurate laboratory diagnosis of typhoid fever: a review and meta-analysis of TUBEX® TF clinical performance. Read the article here: Read the press release here:
